Rob Puopolo, a longstanding partner in Goodwin’s Life Sciences group, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, investment banks and hedge funds that focus on these companies.

Mr. Puopolo also serves on many committees within Goodwin’s Life Sciences business unit, including: the European Committee, the Capital Markets Committee, and the Diversity, Equity + Inclusion Committee, through which he serves as a mentor to associates and junior partners and is an active advocate of the firm’s broader diversity and inclusion efforts.





Mr. Puopolo advises U.S. and European life sciences companies as general outside counsel on a variety of transactions. In addition to providing day-to-day representation and strategic advice to his clients, he regularly handles IPOs and public offerings, mergers and acquisitions, joint ventures and other strategic collaborations.

A selection of Mr. Puopolo’s recent representations include:

Representative Matters



IPOs and Capital Markets
  • Goldman Sachs as lead underwriter in Taysha Gene Therapies, Inc.’s $181 million initial public offering 
  • Goldman Sachs as lead underwriter in Harmony Biosciences Holdings, Inc.’s $148 million initial public offering
  • Goldman Sachs as lead underwriter in Pandion Therapeutics’ $135 million initial public offering
  • CRISPR Therapeutics (Switzerland) in its $518 million, $315 million, $200 million and $130 million public follow-on offerings; its $97 million initial public offering and concurrent private placement; and its $350 million and $600 million at-the-market offerings
  • Avadel Pharmaceuticals (Ireland) in its $65 million financing transaction and its $125 million follow-on public offering
  • Black Diamond Therapeutics in its $231 million initial public offering and $150 million at-the-market offering
  • HOOKIPA Pharma (Austria) in its $84 million initial public offering and its $81 million follow-on public offering
  • BioDelivery Sciences International in its $60 million follow-on public offering
  • Broadfin Capital on its investment in BioDelivery Sciences International’s $50 million follow-on public offering
  • Surface Oncology in its $120 million initial public offering
  • Goldman Sachs as lead underwriter in Arvinas’ $120 million initial public offering and subsequent $115 million and $400 million follow-on public offerings
  • Ra Pharmaceuticals in its $58 million public follow-on offering
Joint Ventures, M&A and Collaborations
  • Avadel Legacy Pharmaceuticals, a wholly-owned subsidiary of Avadel Pharmaceuticals (Ireland), on the sale of its hospital product assets for approximately $42 million
  • BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion
  • Ginkgo Bioworks on its collaboration with Synlogic to accelerate the expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform
  • CRISPR Therapeutics (Switzerland) in an expanded collaboration with Vertex Pharmaceuticals to enhance its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
  • Arvinas on an agreement with Bayer to jointly launch Oerth Bio to leverage Arvinas’ PROTAC technology for agricultural applications
  • BioDelivery Sciences International in its acquisition of U.S. commercial rights to Symproic from Shionogi
  • ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio LLC for $62 million
  • CRISPR Therapeutics (Switzerland) in its collaboration with ViaCyte focused on stem cell therapies for the treatment of diabetes
  • Ginkgo Bioworks in its joint venture with Bayer (Joyn Bio) focused on plant microbiome with an initial investment of $100 million
  • Ginkgo Bioworks in its $14 million partnership with Glycosyn to optimize and scale the production of human milk oligosaccharides (hMOS)
  • Lysosomal Therapeutics in its exclusive option arrangement with Allergan plc with an upfront payment of $150 million
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb with $225 million in upfront and near-term payments
  • F-star Alpha (United Kingdom) in connection with its exclusive option agreement with Bristol-Myers Squibb with payments of up to $475 million
  • CRISPR Therapeutics (Switzerland) in its collaboration with Bayer (Casebia Therapeutics) valued up to $335 million up front
  • Alkermes (Ireland) in the sale of its manufacturing facility and the manufacturing and royalty revenue associated with products manufactured at the facility and global rights to Recro Pharma, Inc., for $170 million
  • Guerbet (France) in a $270 million acquisition of Mallinckrodt's Contrast Media and Delivery Systems business
Venture/Mezzanine Financings
  • 5AM Ventures as lead investor in the $70 million Series A financing of Ensoma
  • 5AM Ventures as lead investor in the $78 million Series A financing and $120 million Series B financing of Artiva Biotherapeutics
  • Monte Rosa Therapeutics in its $32.5 million Series A financing, $96 million Series B financing, and $95 million Series C financing
  • Broadfin Capital as an investor in Sonendo’s $85 million financing
  • Black Diamond Therapeutics in its $85 million Series C financing 
  • Century Therapeutics in its launch with $250 million in financing from Bayer, Versant Ventures and Fujifilm Cellular Dynamics Inc, to advance to multiple programs into the clinic for hematologic and solid malignancies
  • HOOKIPA Pharma (Austria) in its $37.4 million (€33.2 million) Series D financing
  • Pablo Legorreta, founder and CEO of Royalty Pharma, as lead investor in ITBMed’s (Sweden) $67 million equity financing round
  • 5AM Ventures as lead investor in a $45 million Series A financing of Neurogastrx
  • Versant Ventures in collaboration with Bayer Healthcare in launching BlueRock Therapeutics, a next-generation regenerative medicine company, with a Series A financing of $225 million
  • CRISPR Therapeutics (Switzerland) in its $140 million Series B financing
Professional Experience

He has been licensed (inactive) in Massachusetts as a certified public accountant.


Mr. Puopolo is recognized for his growing leadership in the life sciences industry and has been included in numerous legal guides for his expertise. He is recognized by The Legal 500 United States 2020 edition as a “Key Lawyer” and “Next Generation Partner” in the Healthcare: Life Sciences category. He has been recommended by The Legal 500 for Capital Markets: Equity Offerings and repeatedly recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazines.

In The News









J.D., 1998
Suffolk University School of Law
(cum laude)
B.A., 1993
Northeastern University



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique